Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT06112041

The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9.0)

The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors(PRaG9.0)

Status
Not Yet Recruiting
Phase
Phase 2
Study type
Interventional
Enrollment
29 (estimated)
Sponsor
Second Affiliated Hospital of Soochow University · Academic / Other
Sex
All
Age
75 Years
Healthy volunteers
Not accepted

Summary

This is an open-label, single-arm, Phase II investigator-initiated trial of hypofractionated radiotherapy combined with PD-L1 inhibitor sequential GM-CSF and thymopentin for treatment of elderly patients with advanced solid tumors, when the HER-2 positive patients are treated with extra antibody-drug conjugate.

Conditions

Interventions

TypeNameDescription
DRUGADC Combined With Radiotherapy, PD-L1 Sequential GM-CSF and ThymopentinRC48-ADC combined with hypofractionated radiotherapy, PD-L1 inhibitor sequential GM- CSF and Thymopentin

Timeline

Start date
2023-10-25
Primary completion
2026-10-30
Completion
2026-10-30
First posted
2023-11-01
Last updated
2023-11-01

Locations

1 site across 1 country: China

Source: ClinicalTrials.gov record NCT06112041. Inclusion in this directory is not an endorsement.

The Prospective Clinical Study of Precision PRaG Therapy in Elderly Patients With Advanced Solid Malignant Tumors (PRaG9 (NCT06112041) · Clinical Trials Directory